本文選題：酒精性脂肪肝 + 非酒精性脂肪肝�。� 參考：《中國藥理學(xué)通報》2017年06期

【摘要】：白介素1(interleukin-1,IL-1)炎癥因子家族在脂肪肝疾病進(jìn)程中發(fā)揮關(guān)鍵作用。IL-1炎性因子家族參與脂肪肝疾病發(fā)生發(fā)展的各個階段,如肝炎、肝纖維化、肝硬化、肝癌,抑制IL-1信號轉(zhuǎn)導(dǎo)途徑可能是目前治療脂肪肝疾病的有效策略。IL-1炎癥因子家族多環(huán)節(jié)多途徑地整體調(diào)節(jié)脂肪肝疾病的發(fā)生發(fā)展,有望成為有效治療脂肪肝的藥物靶點(diǎn),指導(dǎo)脂肪肝治療藥物的篩選。該文對近年來關(guān)于IL-1炎癥因子家族在酒精性和非酒精性脂肪肝疾病中的作用及機(jī)制研究進(jìn)行全面綜合、整理和歸納。
[Abstract]:Interleukin-1 (IL-1) inflammatory factor family plays a key role in the progression of fatty liver disease. IL-1 inflammatory factor family is involved in various stages of fatty liver disease, such as hepatitis, liver fibrosis, liver cirrhosis, liver cancer. Inhibition of IL-1 signal transduction pathway may be an effective strategy for the treatment of fatty liver disease at present. IL-1 inflammatory factor family regulates the occurrence and development of fatty liver disease in many ways, which is expected to become an effective drug target for the treatment of fatty liver. To guide the screening of drugs for the treatment of fatty liver. The role and mechanism of IL-1 inflammatory factor family in alcoholic and non-alcoholic fatty liver diseases were comprehensively synthesized, summarized and summarized in this paper.
【作者單位】： 江蘇省中藥藥效與安全性評價重點(diǎn)實(shí)驗(yàn)室;江蘇省中藥功效物質(zhì)重點(diǎn)實(shí)驗(yàn)室;南京中醫(yī)藥大學(xué)中藥品質(zhì)與效能國家重點(diǎn)實(shí)驗(yàn)室(培育);
【基金】：國家自然科學(xué)基金資助項(xiàng)目(No 31571455,31401210,31600653,81600483,81270514) 江蘇省自然科學(xué)基金資助項(xiàng)目(No BK20140955) 江蘇省中藥藥效與安全性評價重點(diǎn)實(shí)驗(yàn)室開放課題(No JKLPSE 201502) 江蘇高校優(yōu)勢學(xué)科建設(shè)工程資助項(xiàng)目(No PAPD)
【分類號】：R575.5
，

本文編號：2106714